Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2007

01-09-2007 | Breast Oncology

Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy

Authors: Dalliah Black, MD, Michelle Specht, MD, Janie M. Lee, MD, Francisco Dominguez, MD, Michele Gadd, MD, Kevin Hughes, MD, Elizabeth Rafferty, MD, Barbara Smith, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2007

Login to get access

Abstract

Background

High-risk patients undergoing prophylactic mastectomy (PM) may have unsuspected cancers identified on pathology. The optimum way to identify and manage them is controversial. Magnetic resonance imaging (MRI) may identify occult cancer preoperatively. Sentinel lymph node biopsy (SLNB) allows intraoperative staging and axillary dissection during the same operation. We determined the efficacy and cost of MRI and/or SLNB in managing high-risk PM patients.

Methods

We reviewed 192 PMs in 173 patients from 1999 to 2005. Costs were estimated for MRI and SLNB during PM by the 2005 Medicare Resource-Based Relative Value Scale. We also estimated costs and procedures for the four strategies in a larger hypothetical cohort.

Results

A total of 19 (10%) of 192 PMs contained occult cancers, 14 ductal carcinoma-in-situ (DCIS) and 5 invasive ductal carcinoma (IDC). In 59 patients, MRI detected an IDC but missed two DCIS and an IDC. Positive MRIs generated an additional average cost of $1207 per patient. In 56 PMs with SLNB, 6 occult cancers were found, 5 DCIS and 1 IDC, all with negative SLNBs. Adding a SLNB costs an additional average of $644. A theoretical analysis demonstrated that PM alone costs $808 per patient, PM with SLNB costs $1420, PM with MRI and selective SLNB costs $1774, and PM with routine MRI and SLNB costs $2379.

Conclusions

MRI adds great cost and misses most occult cancers in PMs. SLNB allows the rare patient with occult IDC to avoid axillary dissection but adds cost. Given the low rate of unsuspected invasive cancers and the costs of MRI and SLNB, neither is recommended as standard practice for PM patients.
Literature
1.
go back to reference Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77–84PubMedCrossRef Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77–84PubMedCrossRef
2.
go back to reference Rebbeck T, Friebel T, Lynch H, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055–62PubMedCrossRef Rebbeck T, Friebel T, Lynch H, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055–62PubMedCrossRef
3.
go back to reference Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22PubMedCrossRef Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22PubMedCrossRef
4.
go back to reference Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004;18:CD002748 Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004;18:CD002748
5.
go back to reference McDonnell S, Schaid D, Myers J, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19:3938–43PubMed McDonnell S, Schaid D, Myers J, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19:3938–43PubMed
6.
go back to reference King T, Ganaraj A, Fey J, et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer 2004;10:926–33CrossRef King T, Ganaraj A, Fey J, et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer 2004;10:926–33CrossRef
7.
go back to reference Goldflam K, Hunt K, Gershenwald J, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 2004;101:1977–86PubMedCrossRef Goldflam K, Hunt K, Gershenwald J, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 2004;101:1977–86PubMedCrossRef
8.
go back to reference Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41–5PubMedCrossRef Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41–5PubMedCrossRef
9.
go back to reference Kroll SS, Miller MJ, Schusterman MA, et al. Rationale for elective contralateral mastectomy with immediate bilateral reconstruction. Ann Surg Oncol 1994;1:457–61PubMedCrossRef Kroll SS, Miller MJ, Schusterman MA, et al. Rationale for elective contralateral mastectomy with immediate bilateral reconstruction. Ann Surg Oncol 1994;1:457–61PubMedCrossRef
10.
go back to reference Boughey J, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 2006;107:1440–7PubMedCrossRef Boughey J, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 2006;107:1440–7PubMedCrossRef
11.
go back to reference Kriege M, Brekelmans C, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427–37PubMedCrossRef Kriege M, Brekelmans C, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427–37PubMedCrossRef
12.
go back to reference Stoutjesdijk M, Boetes C, Jager G, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:1095–102PubMedCrossRef Stoutjesdijk M, Boetes C, Jager G, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:1095–102PubMedCrossRef
13.
go back to reference Liberman L, Morris E, Kim C, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. Am J Roentgenol 2003;180:333–41 Liberman L, Morris E, Kim C, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. Am J Roentgenol 2003;180:333–41
14.
go back to reference Lee S, Orel S, Woo I, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003;226:773–8PubMedCrossRef Lee S, Orel S, Woo I, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003;226:773–8PubMedCrossRef
15.
go back to reference Bedrosian I, Schlencker J, Spitz F, et al. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol 2002;9:457–61PubMedCrossRef Bedrosian I, Schlencker J, Spitz F, et al. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol 2002;9:457–61PubMedCrossRef
16.
go back to reference Kim T, Giuliano A, Lyman G. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106:4–16PubMedCrossRef Kim T, Giuliano A, Lyman G. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106:4–16PubMedCrossRef
17.
go back to reference Wilke L, McCall L, Posther K, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13:491–500PubMedCrossRef Wilke L, McCall L, Posther K, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13:491–500PubMedCrossRef
18.
go back to reference Temple L, Baron R, Cody H, et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol 2002;9:654–62PubMedCrossRef Temple L, Baron R, Cody H, et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol 2002;9:654–62PubMedCrossRef
Metadata
Title
Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy
Authors
Dalliah Black, MD
Michelle Specht, MD
Janie M. Lee, MD
Francisco Dominguez, MD
Michele Gadd, MD
Kevin Hughes, MD
Elizabeth Rafferty, MD
Barbara Smith, MD, PhD
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9356-1

Other articles of this Issue 9/2007

Annals of Surgical Oncology 9/2007 Go to the issue